HealthcareServices

Global Cerebral Adrenoleukodystrophy (CALD) Market Projected to Expand at 14.4% CAGR by 2029

November 27, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Cerebral Adrenoleukodystrophy (CALD) Market Expected To Become By 2029 Compared With Its 2025 Level?

The market size for cerebral adrenoleukodystrophy (CALD) has expanded significantly in recent years. It is projected to increase from $6.58 billion in 2024 to $7.54 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.6%. This historical growth can be attributed to heightened awareness of rare diseases, an increase in newborn screening programs, a concentrated focus on neurodegenerative disorders, the availability of Lorenzo’s oil, continued research on peroxisomal disorders, active advocacy from patient support groups, and advancements in healthcare infrastructure.

The cerebral adrenoleukodystrophy (CALD) market size is anticipated to undergo significant expansion in the coming years. It is projected to achieve $12.93 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 14.4%. This projected growth can be attributed to the introduction of gene therapy solutions, the broadening of newborn screening technologies, the advancement of targeted drug delivery systems, increasing investment in rare disease research, greater adoption of digital health tools, a rising need for personalized treatments, alliances between biotechnology and pharmaceutical companies, and improved awareness through global advocacy initiatives. Noteworthy trends for the forecast period include gene editing employing clustered regularly interspaced short palindromic repeats (CRISPR), AI-powered diagnostic algorithms, sophisticated neuroimaging techniques, progress in next-generation sequencing, brain-targeted nanomedicine, wearable devices for neurological monitoring, digital twin simulations for treatment planning, cloud-based genomic data sharing, virtual reality for caregiver training, and blockchain for secure patient data management.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21135&type=smp

What Are The Key Drivers Of Growth In The Cerebral Adrenoleukodystrophy (CALD) Market?

Future expansion of the cerebral adrenoleukodystrophy (CALD) market is anticipated to be driven by increasing healthcare expenditure. This rise in healthcare spending stems from factors such as aging populations, the prevalence of chronic diseases, ongoing medical advancements, escalating drug costs, and broadened health coverage. For cerebral adrenoleukodystrophy (CALD), increased spending facilitates progress in diagnostic tools, finances novel therapies like gene therapy and stem cell transplantation, and enhances patients’ access to specialized care and prompt intervention. As an illustration, the Centers for Medicare And Medicaid Services (CMS), a US federal agency, reported in December 2024 that national health expenditures (NHE) saw a 7.5% increase in 2023, exceeding the gross domestic product (GDP) growth of 6.1%. Projections indicate that from 2023 to 2032, national health expenditures (NHE) will expand at an average yearly rate of 5.6%, causing the health spending proportion of domestic product (GDP) to rise from 17.3% in 2022 to 19.7% in 2032. Consequently, the expansion of the cerebral adrenoleukodystrophy (CALD) market is being propelled by increasing healthcare investment.

Which Key Segments Fueling The Cerebral Adrenoleukodystrophy (CALD) Market?

The cerebral adrenoleukodystrophy (cald)market covered in this report is segmented –

1) By Type Of Treatment: Dietary Management; Medications; Stem Cell Therapy

2) By Patient Age Group: Adults; Children; Infants; Teens

3) By End User: Healthcare Facilities; Patients And Caregivers; Pharmaceutical Companies

Subsegments:

1) By Dietary Management: Lorenzo’s Oil; Omega-3 Fatty Acids; Fatty Acid Supplements

2) By Medications: Corticosteroids; Antioxidants; Anti-inflammatory Drugs

3) By Stem Cell Therapy: Hematopoietic Stem Cell Transplantation (HSCT); Gene Therapy

What Long-Term Trends Will Shape The Future Growth Of The Cerebral Adrenoleukodystrophy (CALD) Industry?

Leading companies engaged in the cerebral adrenoleukodystrophy (CALD) market are prioritizing the development of innovative treatments, including gene therapies, to deliver more effective and sustained solutions for halting disease progression, improving patient outcomes, and potentially offering curative interventions for this rare and severe condition. Gene therapy involves a medical procedure that modifies or substitutes defective genes within a patient’s cells to address or cure diseases. For instance, in September 2022, Bluebird Bio Inc., a US-based biotechnology firm, received accelerated approval for Skysona (elivaldogene autotemcel) from the United States Food and Drug Administration (FDA) aimed at slowing the progression of neurologic dysfunction in boys aged 4-17 who have early, active cerebral adrenoleukodystrophy (CALD). Skysona is a single-administration gene therapy that employs ex-vivo transduction with the Lenti-D lentiviral vector (LVV) to insert functional copies of the ABCD1 gene into a patient’s hematopoietic stem cells (HSCs). This introduced gene enables patients to produce the ALD protein (ALDP), which subsequently aids in the local degradation of very long-chain fatty acids (VLCFAs), a process thought to reduce or potentially prevent further inflammation and demyelination.

Which Key Players Are Driving Competition In The Cerebral Adrenoleukodystrophy (CALD) Market?

Major companies operating in the cerebral adrenoleukodystrophy (CALD) market are Pfizer Inc., Sanofi S.A., Novartis AG, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Poxel S.A., Neuraxpharm Group, Viking Therapeutics Inc., MedDay Pharmaceuticals SAS, Calico Life Sciences, Magenta Therapeutics Inc., SOM Biotech, Minoryx Therapeutics S.L., NeuroVia Inc., SwanBio Therapeutics Inc., Autobahn Therapeutics Inc., Bluebird Bio Inc., Orpheris Inc., Sperogenix Therapeutics, Abliva

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cerebral-adrenoleukodystrophy-cald-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Cerebral Adrenoleukodystrophy (CALD) Market?

North America was the largest region in the cerebral adrenoleukodystrophy (CALD) market in 2024. The regions covered in the cerebral adrenoleukodystrophy (CALD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Cerebral Adrenoleukodystrophy (CALD) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21135&type=smp

Browse Through More Reports Similar to the Global Cerebral Adrenoleukodystrophy (CALD) Market 2025, By The Business Research Company

Cerebral Palsy Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cerebral-palsy-treatment-global-market-report

Genetic Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

Direct To Consumer Dtc Genetic Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/direct-to-consumer-dtc-genetic-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795